Wednesday, February 10, 2010, 7:25am EST - Canadian Markets open in 2 hours and 5 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Affymax, Inc. (AFFY)

 On Feb 9: 20.26 USD   0.00 (0.00%)  
MORE ON AFFY
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Affymax, Inc. (NGM:AFFY) Delayed quote dataEdit
Last Trade: 20.26 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 20.26
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 38.00
Day's Range: N/A - N/A
52wk Range: 11.79 - 25.64
Volume: 0
Avg Vol (3m): 153,427
Market Cap: 387.41M
P/E (ttm): N/A
EPS (ttm): -3.09
Div & Yield: N/A (N/A%)
Affymax, Inc. (AFFY)
1d  5d  3m  6m  1y  2y  5y 
 Add AFFY to Portfolio   Download Data

HEADLINES
• 10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
• Affymax to Present at the 12th Annual BIO CEO & Investor Conference
Business Wire (Mon, Feb 1)
• Amgen Up Despite Q4 Sales, Profit Miss
at Barrons.com (Mon, Jan 25)
• Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide, to Treat Anemia in Chronic Renal Failure
Business Wire (Mon, Jan 25)
• AFFYMAX INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Mon, Jan 11)
• Amgen's Anemia Drug Risks; Vivus Aids Sleep Apnea: BioBuzz
at TheStreet.com (Thu, Jan 7)
• FDA to Review Amgen Drugs: BioBuzz
at TheStreet.com (Thu, Jan 7)
• Affymax to Present at the 28th Annual JP Morgan Healthcare Conference
Business Wire (Tue, Jan 5)
• AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
EDGAR Online (Thu, Dec 10)
• Affymax to Present at Piper Jaffray 21st Annual Healthcare Conference
Business Wire (Tue, Dec 1)
• Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
at TheStreet.com (Mon, Nov 30)
More Headlines for AFFY...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.7
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices